Quantitative and Pathologist-Read Comparison of the Heterogeneity of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer

Modern Pathology - United Kingdom
doi 10.1038/modpathol.2016.186
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Journal of Cancer
Oncology
2017English

Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)

American Journal of Surgical Pathology
AnatomyForensic MedicinePathologySurgery
2016English

Correlation of Programmed Death Ligand-1 (PD-L1) Expression With Clinicopathological Features in Non-Small Cell Lung Carcinoma: Experience From a Tertiary Cancer Care Center in India

Journal of Cancer Therapy
2020English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors

Frontiers in Oncology
Cancer ResearchOncology
2019English

Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice

Cancer cytopathology
Cancer ResearchOncology
2017English

Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy